The finding that the lowering of G6P by metformin was abolished with a glucokinase inhibitor, which lowers G6P is of interest because metformin is known to be ineffective in maturity-onset diabetes of the young linked to inactivating mutations in the GCK gene (51). The gene discussed is GCK; the disease is type 2 diabetes mellitus.